HIV / AIDS in the News

New PAHO course strengthens health workers’ capacity to deliver oral and long-acting PrEP to reduce HIV infections - Pan American Health Organization (PAHO)

 

After 3 decades and millions raised, Gay Bingo host Carlotta Tendant prepares for final act - 6abc Philadelphia

 

Merck Reshapes Leadership As HIV And RSV Prospects Take Center Stage - Yahoo Finance

 

State ducks legal challenge, enacts emergency rule to cut HIV/AIDS medication assistance funding - WUSF

 

How Philly hopes to continue decline in new HIV infections - Billy Penn at WHYY

 

The Fountain of Youth: Groundbreaking study at UofR investigates if HIV drug could extend healthy aging - WHEC.com

 

UR study to test HIV drug’s impact on aging - RochesterFirst

 

UR study to test HIV drug’s impact on aging - RochesterFirst

 

Gilead, Merck & Co. showcase their once-daily, oral options for HIV - FirstWord Pharma

 

Phase III Data Support Single-Tablet HIV-1 Therapy for Older Adults with Resistant Infection - Inside Precision Medicine

 

Gilead, Merck plan to debut new daily HIV pills - Endpoints News

 

Florida HIV medication program faces eligibility cuts this weekend - WCTV

 

ViiV says early-stage data on VH184 for HIV could support twice-yearly dosing - Seeking Alpha

 

Florida uses emergency rule to cut patients off AIDS medication - The Detroit News

 

Pocan Introduces Resolution Recognizing “HIV Is Not a Crime Awareness Day” - Urban Milwaukee

 

New Single-Pill HIV Treatment Shows Promise in Clinical Trials - Fine Day 102.3

 

Gilead reports positive phase 3 data for HIV treatment combo - Investing.com

 

Key facts: Merck reports $65B sales rise; HIV treatment meets trial goals; health division restructured - TradingView

 

State ducks legal challenge, enacts emergency rule to cut HIV/AIDS medication assistance funding - WLRN

 

Pharmacists may soon prescribe HIV prevention drugs - FOX 5 Atlanta

 

Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters

 

Gilead's experimental HIV treatment shows low discontinuation rates in studies - TradingView

 

Novel 1-pill regimen tamps down virus in older adults with HIV, study suggests - CIDRAP

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - GSK

 

Switching to Bictegravir-Lenacapavir Combination Maintains HIV Virologic Suppression in Complex Regimen Patients - Contagion Live

 

what happens if Ryan White ends for HIV AIDS - Infectious Disease Special Edition

 

Once‑every‑4‑months HIV regimen holds virus at bay in ViiV study - Stock Titan

 

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - Business Wire

 

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen - Business Wire

 

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1 - Yahoo Finance